Pentadeca Arginate

Muscle/RecoveryBPC-157 arginate salt / researchExperimental

Pentadeca Arginate is a research peptide in the Wound Healing / Cytoprotective class. The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models.

Calculate Dose

For research use only.

Key Facts

CAS
Molecular Weight (MW)
Half-life
FDA status
Not Approved
Administration Route
subcutaneous
Frequency
Last updated
Aug 30, 2026
Reviewed
Aug 30, 2026

Research summary

Arginate salt form of the BPC-157 pentadecapeptide, marketed as a more stable alternative to the acetate salt. Not FDA-approved. Published research on the arginate form specifically is minimal; nearly all available evidence concerns BPC-157 itself.

Peptide Library's Pentadeca Arginate profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Protocol

Dosage Range
Frequency
Cycle
Administration Route
subcutaneous
Reconstitution Guide

Science

Mechanism of Action

The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models. The arginate counter-ion is claimed to improve stability in solution, but comparative pharmacokinetic data between the salt forms has not been published.

Regulatory & research status

Pentadeca Arginate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Pentadeca Arginate
FDA statusNot Approved
Research statusResearch-only compound; no approval pathway listed
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

Benefits

Potential Side Effects

No side effects listed yet for this entry.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution →

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Pentadeca Arginate: frequently asked questions

What is Pentadeca Arginate?

Arginate salt form of the BPC-157 pentadecapeptide, marketed as a more stable alternative to the acetate salt. Not FDA-approved. Published research on the arginate form specifically is minimal; nearly all available evidence concerns BPC-157 itself.

How does Pentadeca Arginate work?

The peptide sequence is the same as BPC-157, so the proposed mechanism is the same: angiogenic signalling through VEGFR2 and FAK pathways, modulation of the nitric oxide system, and cytoprotective effects on gastrointestinal mucosa reported in animal models. The arginate counter-ion is claimed to improve stability in solution, but comparative pharmacokinetic data between the salt forms has not been published.

Is Pentadeca Arginate FDA approved?

No. Pentadeca Arginate is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to Pentadeca Arginate?

Compounds most often compared with Pentadeca Arginate include BPC-157, TB-500 (Thymosin Beta-4 fragment), Thymosin β4 (Tβ4) and GHK-Cu (Copper Peptide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1

This Pentadeca Arginate profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Pentadeca Arginate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →